The YouTuber suggests GH Research as a 'technology bet' in the psychedelic therapy sector, focusing on a compound that could enable much shorter treatment sessions (30 minutes vs. 6-8 hours). This efficiency could lead to faster commercial adoption and higher patient throughput for clinics. Although it's a pre-revenue biotech with a single compound focus, making it higher risk, the potential for operational leverage in a clinical setting makes it an interesting speculation.
“To take the GH drug, if it works, it's potentially a 30 minute session. So, if you're a clinic, do you want to sell a drug that takes like 6 hours to deliver or 30 minutes to deliver? What do you think?” — ▶ 17:30